liquid-biopsy-analytics-agent

<!--

COPYRIGHT NOTICE

This file is part of the "Universal Biomedical Skills" project.

Copyright (c) 2026 MD BABU MIA, PhD <md.babu.mia@mssm.edu>

All Rights Reserved.

#

This code is proprietary and confidential.

Unauthorized copying of this file, via any medium is strictly prohibited.

#

Provenance: Authenticated by MD BABU MIA

-->

---

name: 'liquid-biopsy-analytics-agent'

description: 'Comprehensive analysis of liquid biopsy data (ctDNA, CTCs) for cancer detection, MRD monitoring, and response tracking.'

keywords:

• liquid-biopsy
• ctdna
• mrd
• cancer-detection
• treatment-response

measurable_outcome: 'Detects circulating tumor DNA with 0.01% sensitivity and accurately predicts treatment response in longitudinal samples.'

allowed-tools:

• read_file
• run_shell_command

---

Liquid Biopsy Analytics Agent

The Liquid Biopsy Analytics Agent provides comprehensive AI-driven analysis of blood-based cancer biomarkers. It integrates circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, and cell-free RNA for multi-cancer early detection (MCED), minimal residual disease (MRD) monitoring, and treatment response assessment.

When to Use This Skill

• For multi-cancer early detection screening from blood samples.
• To monitor minimal residual disease (MRD) after curative treatment.
• When tracking tumor evolution and resistance during therapy.
• For real-time treatment response assessment.
• To detect cancer recurrence before clinical or imaging evidence.

Core Capabilities

1. ctDNA Mutation Analysis: Variant calling, VAF tracking, and clonal evolution from cell-free DNA.

1. Methylation-Based Detection: cfDNA methylation patterns for cancer detection and tissue-of-origin identification.

1. CTC Enumeration & Analysis: AI-powered CTC detection, enumeration, and molecular characterization.

1. Multi-Modal Integration: Combines ctDNA, CTCs, and protein biomarkers with clinical/imaging data.

1. MRD Monitoring: Ultra-sensitive detection of residual disease post-treatment.

1. Response Prediction: AI models predicting treatment response from longitudinal liquid biopsy data.

Analyte Types and Applications

| Analyte | Detection Method | Clinical Use |

|---------|------------------|--------------|

| ctDNA mutations | NGS, ddPCR | Therapy selection, resistance |

| ctDNA methylation | WGBS, targeted | MCED, tissue of origin |

| ctDNA fragmentation | WGS | Cancer detection |

| CTCs | CellSearch, microfluidics | Prognosis, monitoring |

| Exosomes | Immunocapture | Biomarker cargo |

| cfRNA | RT-qPCR, NGS | Gene expression |

Workflow

1. Input: Liquid biopsy data (ctDNA variants, methylation, CTC counts, protein markers).

1. Quality Control: Assess sample quality, input DNA amount, background noise.

1. Variant Analysis: Call mutations, calculate VAF, filter artifacts (CHIP).

1. Multi-analyte Integration: Combine biomarker signals using ML fusion.

1. Clinical Interpretation: Generate actionable insights for treatment decisions.

1. Longitudinal Tracking: Model dynamics for response assessment and recurrence detection.

1. Output: Cancer detection probability, MRD status, treatment recommendations, clonal evolution.

Example Usage

User: "Analyze longitudinal ctDNA data from this lung cancer patient to assess treatment response and detect resistance."

Agent Action:

python3 Skills/Oncology/Liquid_Biopsy_Analytics_Agent/lb_analyzer.py \
    --ctdna_variants longitudinal_ctdna.vcf \
    --timepoints week0,week4,week8,week12 \
    --tumor_markers cea_values.csv \
    --baseline_tissue baseline_tumor.maf \
    --analysis response_resistance \
    --chip_filter true \
    --output lb_report/

AI/ML Models

Multi-Cancer Early Detection (MCED):

• Methylation-based classifiers (sensitivity ~50-80% at 99% specificity)
• Multi-analyte combination models
• Tissue-of-origin prediction
• Integration with imaging and clinical risk

MRD Detection:

• Tumor-informed (personalized panels from tissue)
• Tumor-agnostic (fixed panels, methylation)
• Detection limits: 0.01% - 0.001% VAF

Response Prediction:

• Longitudinal VAF dynamics modeling
• Bayesian evolution frameworks
• Time-to-progression prediction

Clonal Hematopoiesis Filtering

Critical challenge in liquid biopsy interpretation:

| Gene | Prevalence | Action |

|------|------------|--------|

| DNMT3A | 30-40% of CHIP | Filter if VAF stable, no tumor context |

| TET2 | 20-30% | Filter if VAF stable |

| ASXL1 | 10-15% | Filter if VAF stable |

| TP53 | 5-10% | Context-dependent (tumor vs CHIP) |

| Matched WBC | Gold standard | Subtract germline/CHIP variants |

Commercial Platforms (Reference)

| Platform | Technology | Application |

|----------|------------|-------------|

| Guardant360 | ctDNA NGS | Therapy selection |

| FoundationOne Liquid | ctDNA NGS | Comprehensive profiling |

| Galleri | Methylation | MCED screening |

| Signatera | Tumor-informed | MRD monitoring |

| CellSearch | CTC | FDA-cleared enumeration |

Clinical Decision Points

1. Treatment Selection: Actionable mutations (EGFR, ALK, ROS1, BRAF)
2. Response Assessment: ctDNA clearance correlates with outcomes
3. Resistance Detection: Emerging resistance mutations (T790M, C797S)
4. Recurrence Monitoring: Lead time of 3-6 months over imaging

Prerequisites

• Python 3.10+
• NGS variant calling pipelines
• Methylation analysis tools
• Machine learning frameworks

Related Skills

• ctDNA_Analysis - For detailed ctDNA workflows
• Tumor_Clonal_Evolution - For evolutionary analysis
• MRD_Detection - For residual disease focus

Limitations and Considerations

• False positives: CHIP, benign tumors, inflammation
• False negatives: Low shedding tumors, early stage
• Technical variability: Pre-analytical factors critical
• Cost: Multi-analyte panels expensive

Author

AI Group - Biomedical AI Platform

<!-- AUTHOR_SIGNATURE: 9a7f3c2e-MD-BABU-MIA-2026-MSSM-SECURE -->